Rocket Pharmaceuticals (RCKTW) Stock Price, News & Analysis

Company Overview

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW. The company operates research laboratories and manufacturing facilities in the United States, with its headquarters in New York and an additional site in Philadelphia. Rocket has structured its pipeline to advance several product candidates through clinical development while maintaining a preclinical portfolio aimed at expanding its gene therapy platform into additional rare disease indications.

Leadership at Rocket Pharmaceuticals brings together expertise in gene therapy, hematology-oncology and rare disease drug development. The executive team and board of directors include seasoned biopharmaceutical professionals with experience in both clinical development and commercial-scale manufacturing. This blend of scientific rigor and industry experience drives the company’s strategic efforts to secure regulatory approvals and build a sustainable framework for future product launches.

As a specialized gene therapy developer, Rocket Pharmaceuticals is committed to translating cutting-edge science into potential one-time treatments that could dramatically improve patient outcomes. Through targeted clinical trials, partnerships with academic institutions and continuous investment in manufacturing capabilities, the company aims to deliver on its mission of providing lasting therapeutic benefit to children affected by life-threatening genetic disorders.

Key Stats

• Today's Range: $0.03 to $0.04
• 50-Day Range: $0.03 to $0.14
• 52-Week Range: $0.02 to $0.10
• Volume: 45,260 shs
• Average Volume: 23,165 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RCKTW Stock Analysis - Frequently Asked Questions

How have RCKTW shares performed this year?

Rocket Pharmaceuticals' stock was trading at $0.0343 at the start of the year. Since then, RCKTW stock has decreased by 4.7% and is now trading at $0.0327.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RCKTW
• CIK: 1281895
• Web: www.rocketpharma.com
• Phone: 16464409100
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A